Arecor Therapeutics plc
("Arecor" or the "Group")
Arecor to present on Investor Meet Company platform
Cambridge, UK, 27 September 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer, will be providing a live presentation of the Group's recently announced interim results for the six months ended 30 June 2024 via the Investor Meet Company platform, on Thursday 3 October at 3pm BST.
The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard up until 9am BST on Wednesday 2 October 2024, or at any time during the live presentation.
To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit:
https://www.investormeetcompany.com/companies/arecor-therapeutics-plc
Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Panmure Liberum Limited (NOMAD and Joint Broker) |
|
|
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
WG Partners LLP (Joint Broker) |
|
|
Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang |
Tel: +44 (0)203 705 9321 |
|
|
|
|
ICR Consilium |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
|
|
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
